Bluejay Diagnostics, Inc. Income Statement
BJDX|2 years of annual SEC 10-K data (FY2022-FY2023)
Line items include revenue, cost of goods sold, gross profit, operating expenses, interest, taxes, and net income with per-share data across 2 fiscal years. All figures from audited SEC 10-K filings.
At a glance
Revenue
N/A
FY2023
Gross Profit
N/A
FY2023
Operating Income
-$10M
FY2023
Net Income
-$10M
FY2023
Key Data Points
- Altman Z-Score -10.44 (distress zone, below 1.23 threshold)
- Piotroski F-Score: 2/9 criteria passed
- Cash-backed earnings: Operating cash flow exceeds net income
- Negative return on equity: -343.8% ROE
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2023 | FY2022 |
|---|---|---|
| Revenue | - | $249.0K |
| Cost of Revenue | - | $200.1K |
| Gross Profit | - | $48.9K |
| SG&A Expense | $283.4K | $451.4K |
| R&D Expense | $5.7M | $4.2M |
| Operating Income | -$10.3M | -$9.3M |
| Net Income | -$10.0M | -$9.3M |
| EPS (Basic) | -$9.22 | -$0.41 |
| EPS (Diluted) | -$9.22 | -$0.41 |
| Shares Outstanding | 1.0M | 20.1M |
| Gross Margin | - | 19.6% |
| Operating Margin | - | -3741.5% |
| Profit Margin | - | -3733.1% |